The budget includes $400 million in new, dedicated funding for pandemic preparedness and biodefense. These resources will allow ASPR to respond to unforeseen challenges rapidly, prepare for emerging pandemics, and address biodefense threats. For example, ASPR may use the funding to rapidly convert stockpiled drug ingredients into vaccines at the start of an outbreak, support the development of next-generation medical countermeasures, and expand rapid domestic manufacturing of critical vaccines, therapeutics, and other needed healthcare supplies, such as hospital gowns and gloves.
The funding will advance ASPR’s permanent industrial base management office, inclusive of global supply chain awareness, market capabilities, rapid acquisition, and coordination of Defense Production Act (DPA) and Emergency Support Function ESF-8 authorities.